The following items were addressed at the Annual General Meeting of Diamyd
Medical AB (publ) held today:
Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of
the past year and summarized the most significant events that took place during
the fiscal year and after year-end.
The Company's income statements and balance sheets were adopted and the Board
members and the Chief Executive Officer were discharged from liability for the
2011/2012 fiscal year. The Annual General Meeting approved the Board's proposal
that no dividend be paid for the 2011/2012 fiscal year.
Anders Essen-Möller was re-elected as Chairman of the Board and Maria-Teresa
Essen-Möller was re-elected to the Board. Erik Nerpin and Jonas Jendi were
elected as new Board members. Erik Nerpin, born in 1961, is an attorney and
partner at Kilpatrick Townsend in Stockholm. Jonas Jendi, born in 1970, M.Sc.
Economics & Business Administration, has spent the last 10 years managing the
company Cogmed. Cogmed is based on research from the Karolinska Institute and
was acquired by Pearson in 2010. The former Board members Lars Jonsson, Joseph
Janes and Christer Lindberg have declined re-election.
The Annual General Meeting approved the proposed guidelines for remuneration of
the CEO and other senior executives. The Meeting also approved the proposed
remuneration to Board members and the Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company Öhrlings
PricewaterhouseCoopers until the end of the Annual General Meeting 2013.
Principal auditor is the authorized public accountant Eva Blom.
The Annual General Meeting approved the proposed principles for the appointment
of Nomination Committee for the 2013 Annual General Meeting.
The Annual General Meeting resolved to authorize the Board to approve new share
issues for a maximum total of 10 percent of the number of shares on one or more
occasions before the next Annual General Meeting, and permit the Board to
deviate from the shareholders’ preferential rights when so doing. Payment may be
made in cash, through a contribution or by offsetting.
The Annual General Meeting resolved to authorize the Board, for the period until
the next Annual General Meeting, to repurchase series B shares in Diamyd Medical
on Nasdaq OMX Stockholm. The maximum number of shares repurchased shall be such
that Diamyd Medical shares held in treasury from time to time do not exceed ten
percent of all shares in Diamyd Medical.
For more information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical
development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company’s
development project consists of the protein GAD65 for the treatment and
prevention of autoimmune diabetes. A Swedish researcher-initiated Phase II study
is ongoing to evaluate whether GAD65 can prevent type 1 diabetes in children who
are at high risk of developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA) and
the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker:
DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC
Markets and the Bank of New York Mellon (PAL). Further information is available
on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no: 556530-1420
